Evidence map›Paper›PMID 29751845›Full record

ArticleOrphanet journal of rare diseases2018

Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome.

Elsa G Shapiro, Chester B Whitley, Julie B Eisengart

Registry-linked trialAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01870375 (Longitudinal Studies of Brain Structure and Function in MPS Disorders), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01870375 completednot on this map

Longitudinal Studies of Brain Structure and Function in MPS Disorders

TypeobservationalSponsorUniversity of MinnesotaRan2009 to 2019Enrolled100ConditionsMucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis Type IV
3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. MPSI Manifestations and Treatment Outcome: Skeletal Focus.International journal of molecular sciences · 2022
    Review
  9. Differences in MPS I and MPS II Disease Manifestations.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elsa G ShapiroDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Chester B WhitleyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Julie B EisengartDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA. eisen139@umn.edu.ORCID 0000-0001-5340-017X

Funding

Training & EducationU54NS065768 · NINDS · UNIVERSITY OF MINNESOTA · PI WHITLEY, CHESTER B. · 2009 to 2024
$17.7M
NIH HHS NS 29099NIH HHS U54NS065768NINDS NIH HHS U54 NS065768
6 · The paper itself

Abstract

backgroundHurler syndrome (MPS IH), the severe, neurodegenerative form of type one mucopolysaccharidosis, is associated with rapid neurocognitive decline during toddlerhood and multi-system dysfunction. It is now standardly treated with hematopoietic cell transplantation (HCT), which halts accumulating disease pathology and prevents early death. While norm-based data on developmental functioning in untreated children have previously demonstrated neurocognitive decline, advances in methodology for understanding the cognitive functioning of children with neurodegenerative diseases have highlighted that the previous choice of scores to report results was not ideal. Specifically, the lowest possible norm-based score is 50, which obscures the complete range of cognitive functioning at more advanced stages of neurodeterioration. To a set of cognitive data collected on a sample of untreated children, we applied a modern method of score analysis, calculating a developmental quotient based on age equivalent scores, to reveal the full range of cognitive functioning beneath this cutoff of 50, uncovering new information about the rapidity of decline and the profound impairment in these children.

resultsAmong 39 observations for 32 patients with untreated Hurler syndrome, the full array of cognitive functioning below 50 includes many children in the severely to profoundly impaired range. The loss of skills per time unit was 14 points between age 1 and 2. There was a very large range of developmental quotients corresponding to the norm-based cutoff of 50.

conclusionsThis report enables clarification of functioning at levels that extend beneath the floor of 50 in previous work. At the dawn of newborn screening and amidst a proliferation of new therapies for MPS I, these data can provide crucial benchmark information for developing treatments, particularly for areas of the world where transplant may not be available.

Indexed as

ChildChild, PreschoolFemaleHumansInfant, NewbornMaleMucopolysaccharidosis INeonatal ScreeningNeurodevelopmental DisordersAge equivalentCognitive declineDevelopmental quotientMucopolysaccharidosis type INatural historyNeurodegenerative diseaseNewborn screening

Identifiers

PMID29751845
PMCPMC5948735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.